Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Refractory Cough Clear all
Completed Phase 1 Interventional

Cough Desensitization Therapy: Pilot 2

NCT05226299
View directory record Official record
Conditions
Cough
Interventions
Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer, Saline
Biological
Lead sponsor
University of Montana
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 22, 2026, 4:36 AM EDT
Active, not recruiting Phase 3 Interventional

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777
View directory record Official record
Conditions
Cough, Refractory Chronic Cough
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 80 Years
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
57
States / cities
Foley, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

NCT04562155
View directory record Official record
Conditions
Refractory and/or Unexplained Chronic Cough
Interventions
BAY1817080, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Largo, Florida • White Marsh, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 22, 2026, 4:36 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

NCT03979638
View directory record Official record
Conditions
Chronic Refractory Cough
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
San Diego, California • San Jose, California • Largo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

NCT03622216
View directory record Official record
Conditions
Chronic Cough
Interventions
Bradanicline, Placebo
Drug
Lead sponsor
Attenua, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
La Mesa, California • Mission Viejo, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 22, 2026, 4:36 AM EDT
Not listed Early Phase 1 Interventional

Group Telehealth Behavioral Cough Suppression Therapy

NCT06706765
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
Behavioral Treatment
Behavioral
Lead sponsor
University of Montana
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Not applicable Interventional Results available

Internet-Behavioral Cough Suppression Therapy

NCT05770401
View directory record Official record
Conditions
Cough, Chronic Disease
Interventions
Internet-Behavioral Cough Suppression Therapy, Sham Treatment
Behavioral
Lead sponsor
University of Montana
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04471337
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 22, 2026, 4:36 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

NCT05120934
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG, Duloxetine 60 MG, Placebo 30 MG, Placebo 60 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

NCT02993822
View directory record Official record
Conditions
Chronic Refractory Cough
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
46
States / cities
Chandler, Arizona • Los Angeles, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

NCT01703923
View directory record Official record
Conditions
Chronic Refractory Cough
Interventions
FP01, placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
8
States / cities
San Jose, California • Largo, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Early Phase 1 Interventional Results available

Cough Desensitization Therapy for Cough Hypersensitivity Syndrome

NCT04256733
View directory record Official record
Conditions
Cough
Interventions
Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer, Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer
Biological
Lead sponsor
University of Montana
Other
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 22, 2026, 4:36 AM EDT
Recruiting Not applicable Interventional

Cough Management Wellness App for Refractory or Unexplained Chronic Cough

NCT07070895
View directory record Official record
Conditions
Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity
Interventions
Cough Management, CoughMonitor Suite
Behavioral · Device
Lead sponsor
Hyfe Inc
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

Pilot of Zinc Acetate to Improve Chronic Cough

NCT03135522
View directory record Official record
Conditions
Cough
Interventions
Zinc Acetate 50 Mg Oral Capsule, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 22, 2026, 4:36 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446
View directory record Official record
Conditions
Refractory or Unexplained Chronic Cough
Interventions
NOC-110, Placebo
Drug · Other
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
68
States / cities
Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 4:36 AM EDT
Recruiting No phase listed Observational

Laryngeal Cryotherapy for Refractory Neurogenic Cough

NCT05665244
View directory record Official record
Conditions
Upper-Airway Cough Syndrome
Interventions
Laryngeal cryotherapy, Cryoprobe
Procedure · Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 22, 2026, 4:36 AM EDT
Recruiting Phase 2 Interventional

Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough

NCT06960759
View directory record Official record
Conditions
Chronic Cough (CC), Refractory Chronic Cough, Unexplained Chronic Cough
Interventions
BCS+inactive, BCS+active
Behavioral · Combination Product
Lead sponsor
University of Montana
Other
Eligibility
18 Years to 99 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Atlanta, Georgia • Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 4:36 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough

NCT05110144
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG, Amitriptyline 50 MG, Placebo 30 MG, Placebo 60 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

NCT05660850
View directory record Official record
Conditions
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions
GDC-6599, GDC-6599-matching placebo, Mannitol
Drug · Other · Diagnostic Test
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Northridge, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT04678206
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
55
States / cities
Peoria, Arizona • Little Rock, Arkansas • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

NCT03282591
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
5 mg Serlopitant Tablets, Matching Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
29
States / cities
Los Angeles, California • Mission Viejo, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 3 Interventional

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191
View directory record Official record
Conditions
Cough, Refractory Chronic Cough
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 80 Years
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
67
States / cities
Jasper, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

An 8-Week Refractory Chronic Cough Study (MK-7264-021)

NCT02612623
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
Gefapixant, Placebo (for gefapixant)
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Mission Viejo, California • San Jose, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 22, 2026, 4:36 AM EDT